Drugs /

hpv-16 e6 peptides vaccine/candida albicans extract

Back to Drugs List

Overview

NCI Definition [1]:
A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with the extract of Candida albicans, with potential immunomodulating activity. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the candida albicans may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions. Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV.

Clinical Trials

View Clinical Trials for hpv-16 e6 peptides vaccine/candida albicans extract

Hpv-16 e6 peptides vaccine/candida albicans extract has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating hpv-16 e6 peptides vaccine/candida albicans extract, 1 is phase 1/phase 2 (1 open).

Head and neck squamous cell carcinoma is the most common disease being investigated in hpv-16 e6 peptides vaccine/candida albicans extract clinical trials [2].

Drug Details

Synonyms [2]:
hpv-16 e6 peptides vaccine/candin
NCIT ID [1]:
C102874

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.